Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease.

ABSTRACT: Sickle-cell disease (SCD) leads to recurrent vaso-occlusive crises, chronic end-organ damage, and resultant physical, psychological, and social disabilities. Although hematopoietic stem-cell transplantation (HSCT) is potentially curative for SCD, this procedure is associated with well-recognized morbidity and mortality and thus is ideally offered only to patients at high risk of significant complications. However, it is difficult to identify patients at high risk before significant complications have occurred, and once patients experience significant organ damage, they are considered poor candidates for HSCT. In turn, patients who have experienced long-term organ toxicity from SCD such as renal or liver failure may be candidates for solid-organ transplantation (SOT); however, the transplan

SUBMITTER: Hosoya H 

PROVIDER: S-EPMC5851417 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature